Hangzhou Tigermed Consulting Co., Ltd (HNGZY)

Market Cap	7.77B +41.2%
Revenue (ttm)	921.64M -3.5%
Net Income	85.99M -36.1%
EPS	0.10 -35.6%
Shares Out	n/a
PE Ratio	90.39
Forward PE	45.02
Dividend	0.03 (0.72%)
Ex-Dividend Date	Jun 13, 2025

Volume	612
Average Volume	454
Open	4.000
Previous Close	4.000
Day's Range	4.000 - 4.000
52-Week Range	4.000 - 4.300
Beta	0.70
RSI	n/a
Earnings Date	Mar 31, 2026

About HNGZY

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 10,251
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNGZY

Financial Performance

In 2024, HNGZY's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY